pharmaphorum15m
Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...
The Lever20m
You’ve Already Paid $6 Billion For Weight-Loss Drugs You Can’t Afford
U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...